THE CLINICAL POTENTIAL OF LINEX FORTE® IN SYSTEMIC ANTIBIOTIC THERAPY
https://doi.org/10.21518/2079-701X-2017-5-94-98
Abstract
The article tells about the prevalence and etiopathogenesis of antibiotic-associated diarrhea and the main pathogens focusing on Clostridium difficile. The methods of treatment of the disease are described. The article is largely an overview of research reports on the use of probiotics for the prevention and treatment of antibiotic-associated diarrhea. In accordance with the declared topic, the author’s original study of the probiotic complex Linex® Forte is presented.
About the Authors
E. Y. Plotnikova
Kemerovo State Medical University
Russian Federation
Russian Federation
MD, Prof.
Y. V. Zakharova
Kemerovo State Medical University
Russian Federation
Russian Federation
PhD in medicine
T. Y. Gracheva
Kemerovo State Medical University
Russian Federation
Russian Federation
MD, Prof
References
1. Wistrom J, Norrby SR, Myhre EB. Frequency of antibioticassociated diarrhoea in 2462 antibiotictreated hospitalized patients: a prospective study. J Antimicrob Chemother, 2001, 47: 4350.
2. Bartlett JG. Antibioticassociated diarrhea. N Engl J Med, 2002, 346(5): 334339.
3. LaRosa M, Bottaro G, Gulino N. Prevention of antibioticassociated diarrhea with Lactobacillus sporogens and fructooligosaccharides in children: a multicentric doubleblind vs. placebo study. Minerva Pediatr, 2003, 55: 447452.
4. Turck D, Bernet JP, Marx J et al. Incidence and risk factors of oral antibioticassociated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr, 2003, 37: 2226.
5. McFarland LV. Probiotics and Diarrhea. Ann Nutr Metab, 2010, 57(1): 1011.
6. Закордонец Л.В., Крамарев С.А., Береговая Т.В., Толстанова А.Н., Довбинчук Т.В. Антибиотикассоциированная диарея: механизмы развития и возможности коррекции. Здоровье ребенка, 2013, 7: 69-73.
7. Vonberg RP, Reichardt C, Behnke M et al. Cost of nosocomial Clostridium difficileassociated diarrhea. J Hosp Infect, 2008, 70: 1520.
8. Hu Y et al. Exploring on the Status, Reasons and Countermeasures of Antibiotics Abuse. Chinese Journal of Social Medicine, 2013: 128-130.
9. McFarland LV. Epidemiology, risk factors and treatments for antibioticassociated diarrhea. Dig Dis., 1998, 16: 292307.
10. Lusk RH, Fekety FR, Silva JJ, Bodendorfer T, Devine BJ, Kawanishi H, Korff L, Nakauchi D, Rogers S, Siskin SB. Gastrointestinal side effects of clindamycin and ampicillin therapy. J Infect Dis, 1977, 135: 111119.
11. Плотникова Е.Ю., Захарова Ю.В. Роль пробиотиков в профилактике и лечении антибиотикассоциированной диареи. Доказательная гастроэнтерология, 2013, 4(2): 51-57.
12. Шевяков М.А. Антибиотик-ассоциированная диарея и кандидоз кишечника: возможности лечения и профилактики. Антибиотики и химиотерапия, 2004, 10(49): 26-29.
13. Плотникова Е.Ю., Захарова Ю.В. Место пробиотиков в профилактике и лечении антибиотик-ассоциированной диареи. Терапевтический архив, 2015, 5(85): 127-131.
14. Modi N, Wilcox MH. Evidence of antibiotic induced Clostridium perfringens diarrhoea. J Clin Pathol, 2001, 54: 748–751.
15. Vaishnavi C, Kaur S, Singh K. Clostridium perfringens type A & antibiotic associated diarrhoea. Indian J Med Res, 2005, 122: 52–56.
16. Gravet A, Rondeau M, Harf-Monteil C, Grunenberger F, Monteil H, Scheftel JM, Prevost G. Predominant Staphylococcus aureus isolated from antibiotic-associated diarrhea is clinically relevant and produces enterotoxin A and the bicomponent toxin LukE-LukD. J Clin Microbiol, 1999, 37: 4012–4019.
17. Beaugerie L, Metz M, Barbut F, Bellaiche G, Bouhnik Y, Raskine L, Nicolas JC, Chatelet FP, Lehn N, Petit JC. Klebsiella oxytoca as an agent of antibiotic-associated hemorrhagic colitis. Clin Gastroenterol Hepatol, 2003, 1: 370–376.
18. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance/threatreport-2013. Accessed 29 Mar 2016.
19. Kim SW, Peck KR, Jung SI, Kim YS, Kim SM, Lee NY, Song JH. Pseudomonas aeruginosa as a potential cause of antibiotic-associated diarrhea. J Korean Med Sci, 2001, 16: 742-744.
20. Levine J, Dykoski RK, Janoff EN. Candidaassociated diarrhea: a syndrome in search of credibility. Clin Infect Dis, 1995, 21: 881-886.
21. Barbut F, Petit JC. Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect, 2001, 7: 405–10.
22. McFarland LV, Goh S. Preventing Pediatric Antibiotic-Associated Diarrhea and Clostridium difficile Infections with Probiotics: a meta-analysis. World J Meta-analysis, 2013, 1: 102-120.
23. Xie C, Li J, Wang K, Li Q, Chen D. Probiotics for the prevention of antibiotic-associated diarrhoea in older patients: a systematic review. Travel Med Infect Dis, 2015, 13: 128-134.
24. O’Connor JR, Johnson S & Gerding DN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology, 2009, 136: 1913-1924.
25. Cohen SH et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infection control and hospital epidemiology, 2010, 31: 431-455.
26. Kuijper EJ et al. Update of Clostridium difficileassociated disease due to PCR ribotype 027 in Europe. Euro surveillance: bulletin Europeen sur les maladies transmissibles. European communicable disease bulletin, 2007, 12: E1-2.
27. McDonald LC et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infection control and hospital epidemiology, 2007, 286: 140-145.
28. Collins DA, Riley TV. Routine detection of Clostridium difficile in Western Australia. Anaerobe, 2016, 37: 34-37.
29. Baldoni D, Gutierrez M, Timmer W. Dingemanse J. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. The Journal of antimicrobial chemotherapy, 2014, 69: 06-714.
30. McDonald LC et al. An epidemic, toxin gene-variant strain of Clostridium difficile. The New England journal of medicine, 2005, 353: 2433-2441.
31. McFarland LV. Update on the changing epidemiology of Clostridium difficile-associated disease. Nature clinical practice. Gastroenterology & hepatology, 2008, 5: 40-48.
32. Warny M et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet, 2005, 366: 1079-1084.
33. Rea MC., et al. Effect of broadand narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108(l): 4639–4644.
34. Magill SS et al. Multistate point-prevalence survey of health care-associated infections. The New England journal of medicine, 2014, 370: 1198–1208.
35. Surawicz CM, Brandt LJ, Binion DG et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol, 2013, 108(4): 478-498.
36. Bagdasarian N, Rao K, Malani PN Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA, 2015, 313(4): 398-408.
37. McFarland LV, Ozen M, Dinleyici EC, Goh S. Comparison of pediatric and adult antibioticassociated diarrhea and Clostridium difficile infections. World J Gastroenterol, 2016 Mar 21, 22(11): 3078-3104.
38. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol, 2011, 9: 1044-9.
39. Cremonini F, Di Caro S, Nista EC, et al. Metaanalysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther, 2002, 16: 1461-7.
40. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. American Journal of Gastroenterology, 2006, 101: 812-22.
41. Malfertheiner P, Megraud F, O’Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 2007, 56: 772-81.
42. Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Alimentary Pharmacology & Therapeutics, 2012, 35(12): 1355-1369.
43. Lau SM Christine, Ronald S. Chamberlain Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. International Journal of General Medicine, 2016, 22(9): 27-37.
44. Jafarnejad S, Shab-Bidar S, Speakman JR., Parastui K, Daneshi-Maskooni M, Djafarian K. Probiotics Reduce the Risk of Antibiotic-Associated Diarrhea in Adults (18–64 Years) but Not the Elderly (>65 Years). A Meta-Analysis. Nutrition in Clinical Practice, 2015, 31(4): 502-513.
45. Goldenberg JZ, Lytvyn L, Steurich J, Parkin P, Mahant S, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev, 2015 Dec 22, 12: CD004827.
46. Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, Johnsen B, Shekelle PG. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA, 2012 May 9, 307(18): 1959-69.
47. Vaughan RB. The romantic rationalist: a study of Elie Metchnikoff. Med Hist, 1965, 9: 201-215.
48. Verna EC, Lucak S. Use of probiotics in gastrointestinal disorders: what to recommend? Therap Adv Gastroenterol, 2010 Sep, 3(5): 307-319.
49. FAO/WHO. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Expert. Consultation. Report, 2001: 1-34.
50. Chatterjee S, Kar P, Das T, Ray et al. Randomised placebo-controlled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated diarrhoea. J Assoc Physicians India, 2013, 61: 708-12.
51. Black F, Einarsson K, Lidbeck A, et al. Effect of lactic acid producing bacteria on the human intestinal microflora during ampicillin treatmen. Scand J Infect Dis, 1991, 23: 247.
52. de Vrese M. Effects of probiotic bacteria on gastrointestinal symptoms, Helicobacter pylori activity and antibiotics-induced diarrhea. Gastroenterology, 2003, 124: A560.
53. de Vrese M, Kristen H, Rautenberg P et al. Probiotic lactobacilli and bifidobacteria in a fermented milk product with added fruit preparation reduce antibiotic associated diarrhea and Helicobacter pylori activity. J Dairy Res, 2011 Nov, 78(4): 396-403.
54. Sheu BS, Wu JJ, Lo CY et al. Impact of supplement with Lactobacillusand Bifidobacteriumcontaining yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther, 2002 Sep, 16(9): 1669-75.
Review
For citations:
Plotnikova EY, Zakharova YV, Gracheva TY. THE CLINICAL POTENTIAL OF LINEX FORTE® IN SYSTEMIC ANTIBIOTIC THERAPY. Meditsinskiy sovet = Medical Council. 2017;(5):94-98. (In Russ.) https://doi.org/10.21518/2079-701X-2017-5-94-98
Views:
3539
Email this article 